BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
Key Highlights
- ➤Q3 revenue €1,289.2 million, down from €1,518.9 million year over year
- ➤Q3 adjusted net profit €440.9 million, down from €752.5 million
- ➤2026 revenue guidance raised to €1.7–1.9 billion from €1.6–1.9 billion
- ➤Cash, equivalents and security investments totaled €16.2 billion at September 30
- ➤Pumitamig advanced toward first global Phase 3 ADC combination trial in TNBC
Expert Statements
Ugur Sahin, Chief Executive Officer and Co-Founder of BioNTech
“As 2026 draws to a close, the achievement of numerous important milestones throughout the year demonstrates our commitment to advancing our oncology pipeline, and our combination therapy strategy continues to gain momentum, underscored by the announced first global Phase 3 trial of pumitamig in combination with an antibody-drug conjugate”
Ugur Sahin, Chief Executive Officer and Co-Founder of BioNTech
“With a growing pipeline, key registrational trials, strategic partnerships, and financial strength, BioNTech is well positioned for its next phase of growth as we advance toward becoming a diversified, multi-product company by 2030.”
Ramón Zapata, Chief Financial Officer at BioNTech
“Our performance in the third quarter allowed us to narrow our full-year 2026 revenue guidance to the upper end of the previous guidance range,”
Ramón Zapata, Chief Financial Officer at BioNTech
“Fueled by our financial strength, we continue to focus our investments on our prioritized late-stage oncology programs. While we further enhance our operational efficiency and cost discipline, we return capital to shareholders through our share repurchase program. Together, these steps are aimed at creating sustainable long-term value.”
* Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecan * Advanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead’s TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval * Presented data demonstrating gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer * Launched variant-adapted COVID-19 vaccine for the 2026/2027 vaccination season in multiple regions worldwide * Third quarter 2026 revenues of €1,289.2 million(1), adjusted(2) R&D expenses of €578.5 million (IFRS R&D expenses of €748.1 million), and adjusted SG&A(3) expenses of €178.5 million * Raised full-year 2026 revenue guidance midpoint and updated range to €1.7–1.9 billion, and maintained strong financial position with cash, cash equivalents and security investments of €16.2 billion(4) Conference call and webcast scheduled for November 3, 2026, at 8:00 a.m. EST (2:00 p.m. CET)
Get started
Create a free account to read the full story.